Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolution of the frontal aslant tract and implications for primate vocalization and human speech.

Nature communications·2026
Same author

DECODE: An innovative tool to aid cross-linguistic neuropsychological assessment.

The Clinical neuropsychologist·2026
Same author

Anosognosia for aphasia: impact of statistical biases and aphasia severity.

Journal of clinical and experimental neuropsychology·2026
Same author

The status and interpretation of neuropsychological evidence: Commentary on 'No evidence yet for functional independence of verbal short-term memory and long-term verbal knowledge' by Majerus, Cowan and Oberauer (2026).

Journal of neuropsychology·2026
Same author

Graphic transmutations identify the phenomenon of meaningless pictures remembered as familiar objects.

Scientific reports·2026
Same author

When repeated presentation of visual feature bindings does and does not result in learning: Visual short-term and long-term memory are distinct but work in tandem.

Memory & cognition·2025

Related Experiment Video

Updated: Apr 30, 2026

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K

No dual-task practice effect in Alzheimer's disease.

Jennifer A Foley1, Gianna Cocchini, Robert H Logie

  • 1a Department of Neuropsychology , National Hospital for Neurology and Neurosurgery , Queen Square, London , UK.

Memory (Hove, England)
|May 3, 2014
PubMed
Summary

Dual tasking, the ability to do two things at once, is impaired in Alzheimer's disease (AD) but not in healthy aging. This reliable assessment may aid early AD diagnosis and monitoring.

Keywords:
Alzheimer's diseaseAssessmentDual taskPracticeReliability

More Related Videos

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

12.6K
Revised and Neuroimaging-Compatible Versions of the Dual Task Screen
07:52

Revised and Neuroimaging-Compatible Versions of the Dual Task Screen

Published on: October 5, 2020

3.0K

Related Experiment Videos

Last Updated: Apr 30, 2026

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

12.6K
Revised and Neuroimaging-Compatible Versions of the Dual Task Screen
07:52

Revised and Neuroimaging-Compatible Versions of the Dual Task Screen

Published on: October 5, 2020

3.0K

Area of Science:

  • Neuroscience
  • Cognitive Psychology
  • Gerontology

Background:

  • Alzheimer's disease (AD) diagnosis relies on identifying cognitive decline.
  • Current cognitive tests have practice effects, reducing reliability.
  • Dual tasking is impaired in AD but not healthy aging, suggesting diagnostic potential.

Purpose of the Study:

  • To investigate the reliability of dual-task assessment in Alzheimer's disease.
  • To determine if dual-tasking impairment is specific to AD and unaffected by healthy aging or practice effects.

Main Methods:

  • Simultaneous performance of digit recall and tracking tasks was assessed.
  • Eight individuals with AD, eight healthy older adults, and eight healthy younger adults participated.
  • Testing occurred across six sessions to evaluate practice effects.

Main Results:

  • Dual-task performance was significantly impaired in individuals with AD.
  • Healthy older adults and younger adults showed no impairment in dual-task performance.
  • No improvement in dual-task performance was observed in any group despite repeated exposure.

Conclusions:

  • Dual-task assessment is a reliable measure for monitoring Alzheimer's disease progression.
  • Dual tasking involves a specific cognitive function impaired in the Alzheimer's disease brain.
  • This assessment shows potential for early Alzheimer's disease diagnosis due to its specificity.